NARF Activators
NARF activators comprise a diverse array of chemical compounds that indirectly stimulate the functional activity of the NARF protein through various unique and specific signaling pathways or biological processes. Compounds such as Forskolin and IBMX elevate intracellular levels of cyclic nucleotides, including cAMP, which in turn activate PKA. Activated PKA can phosphorylate substrates that influence the signaling pathways associated with NARF, thereby enhancing its functional activity. Similarly, PMA, as a PKC activator, can phosphorylate and modulate proteins downstream that may intersect with NARF signaling, leading to its increased activity. Epigallocatechin Gallate, through its inhibition of certain kinases, and the PI3K inhibitors LY294002 and Wortmannin, can shift cellular signaling dynamics, potentially relieving negative regulation and favoring the activation of NARF.
Further augmenting the activity of NARF, U0126 disrupts the MEK-ERK signaling axis, which could release NARF from negative regulation by ERK. The lipid signaling mediator, Sphingosine-1-phosphate, and the SERCA pump inhibitor Thapsigargin both modulate intracellular signaling mechanisms-lipid and calcium-dependent, respectively-that can lead to the enhanced activity of NARF. Genistein, by inhibiting tyrosine kinase activity, and Staurosporine,, through broad kinase inhibition, may reduce competitive phosphorylation events, thereby allowing NARF pathways to become more active. Additionally, A23187, by increasing intracellular calcium levels, can activate calcium-dependent signaling pathways that are crucial for the functional enhancement of NARF. Collectively, these compounds, by targeting specific signaling molecules and pathways, indirectly facilitate the activation and functional enhancement of NARF without the need for upregulating its expression or direct activation.
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $76.00 $150.00 $725.00 $1385.00 $2050.00 | 73 | |
Forskolin, by increasing intracellular cAMP levels, can activate protein kinase A (PKA). PKA, in turn, can phosphorylate various substrates that are involved in the activation of the NARF protein's functional pathways. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $159.00 $315.00 $598.00 | 34 | |
Isobutylmethylxanthine (IBMX) is a nonspecific inhibitor of phosphodiesterases, which prevents the breakdown of cAMP and cGMP, leading to their accumulation. The increased levels of these cyclic nucleotides can enhance the activity of PKA or PKG, thereby indirectly enhancing NARF function. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $40.00 $129.00 $210.00 $490.00 $929.00 | 119 | |
Phorbol 12-myristate 13-acetate (PMA) is an activator of protein kinase C (PKC). PKC activation can lead to the phosphorylation and activation of downstream targets that could enhance NARF activity within its specific signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $42.00 $72.00 $124.00 $238.00 $520.00 $1234.00 | 11 | |
Epigallocatechin Gallate (EGCG) is known to inhibit certain protein kinases, which may lead to reduced negative regulation of NARF, thus indirectly increasing its activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor. Inhibition of PI3K can shift the balance of intracellular signaling pathways, potentially leading to enhanced NARF activity through alternative routes. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor, and like LY294002, can alter signaling pathways to favor the activation of NARF. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $162.00 $316.00 $559.00 $889.00 $1693.00 | 7 | |
Sphingosine-1-phosphate acts via its receptors to modulate a variety of signaling pathways which can lead to the activation of NARF by affecting downstream signaling molecules. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $94.00 $349.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor leading to increased cytosolic calcium levels, which can activate calcium-dependent signaling pathways that enhance the activity of NARF. | ||||||
Genistein | 446-72-0 | sc-3515 sc-3515A sc-3515B sc-3515C sc-3515D sc-3515E sc-3515F | 100 mg 500 mg 1 g 5 g 10 g 25 g 100 g | $26.00 $92.00 $120.00 $310.00 $500.00 $908.00 $1821.00 | 46 | |
Genistein, a tyrosine kinase inhibitor, can lead to reduced competitive phosphorylation, potentially enhancing the activity of NARF through less inhibited signaling pathways. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor that could lead to selective activation of NARF pathways by lifting the inhibition on certain kinases that are negative regulators of NARF. | ||||||